57536-86-4

Usage

Uses

Used in Pharmaceutical Applications:
1-(1-NAPHTHYL)PIPERAZINE HYDROCHLORIDE is used as a potential CNS stimulant for the development of new drugs targeting various neurological and psychological disorders. Its ability to stimulate the CNS makes it a candidate for treating conditions that may benefit from enhanced central nervous system activity.
Used in Scientific Research:
In the field of scientific research, 1-(1-NAPHTHYL)PIPERAZINE HYDROCHLORIDE is used as a chemical compound in experiments and studies, contributing to the understanding of its properties and potential applications in medicine and chemistry.
Used in Organic Synthesis:
1-(1-NAPHTHYL)PIPERAZINE HYDROCHLORIDE is used as a building block in organic synthesis, allowing for the creation of other chemical compounds that may have various applications in different industries.
Used in Chemical Compound Creation:
As a component in the creation of new chemical compounds, 1-(1-NAPHTHYL)PIPERAZINE HYDROCHLORIDE expands the range of substances available for use in various fields, including but not limited to pharmaceuticals, materials science, and chemical research.

InChI:InChI=1/C14H16N2/c1-2-6-13-12(4-1)5-3-7-14(13)16-10-8-15-9-11-16/h1-7,15H,8-11H2

Upstream product

• 43204-63-3 bis(2-bromoethyl)amine hydrobromide 
• 134-32-7 1-amino-naphthalene 
• 110-85-0 piperazine 
• 90-11-9 1-Bromonaphthalene 
• 90-13-1 1-Chloronaphthalene 
• 6163-58-2 tris-(o-tolyl)phosphine 
• 511231-16-6 1-benzyl-4-(1-naphthyl)piperazine 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 
• 552-46-5 1-naphthylamine hydrochloride 

Downstream Products

• 117922-99-3 4-(4-(2-(4-(Naphth-1-yl)piperazinyl)ethyl)phenyl)-1,2,3-thiadiazole 
• 117923-16-7 4-{4-[2-(4-Naphthalen-1-yl-piperazin-1-yl)-ethyl]-phenyl}-thiazol-2-ol 
• 117923-04-3 4-(4-(2-(4-(1-Naphthyl)piperazinyl)ethyl)phenyl)-2-methylthiazole 
• 117923-13-4 4-(4-(2-(4-(1-naphthyl)piperazinyl)ethyl)phenyl)-2-aminothiazole 
• 117923-14-5 4-(4-(2-(4-(1-naphthyl)piperazinyl)ethyl)phenyl)-2-amino-5-methylthiazole 
• 117923-18-9 4-(4-(2-(4-(1-Naphthyl)piperazinyl)ethyl)phenyl)-2-methylaminothiazole 
• 190126-27-3 4-[2-(3-nitro-4-aminophenyl)-ethyl]-1-(1-naphthyl)piperazine 
• 511231-16-6 1-benzyl-4-(1-naphthyl)piperazine 
• 126652-60-6 1-Methyl-3-{2-[4-(1-naphthyl)-1-piperazinyl]ethyl}-6-phenyl-2,4(1H,3H)-pyrimidinedione 
• 126652-73-1 1-Methyl-6-(3-methylphenyl)-3-{2-[4-(1-naphthyl)-1piperazinyl]ethyl}-2,4(1H,3H)-pyrimidinedione 
• 958264-64-7 C₂₃H₂₆N₄O₃ 
• 1610998-63-4 N-(3-methoxyphenyl)-N-methyl-3-[4-(naphthalen-1-yl)piperazin-1-yl]propanamide 

Relevant academic research and scientific papers

5-HT1 and 5-HT2 Binding Characteristics of Some Quipazine Analogues

Arylpiperazines, such as 1-(3-trifluoromethylphenyl)piperazine (TFMPP) and its chloro analogue mCPP, are 5-HT1 agonists, whereas quipazine, i.e., 2-(1-piperazino)quinoline, appears to be a 5-HT2 agonist.Radioligand binding studies using rat cortical membrane homogenates and drug discrimination studies using rats trained to discriminate a 5-HT1 agonist (i.e., TFMPP) or a 5-HT2 agonist (i.e., 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) from saline reveal that quipazine and its 1-deaza analogue 2-naphthylpiperazine (2-NP) bind at 5-HT1 and 5-HT2 sites but produce stimulus effects similar to those of DOM.A structurally related compound, 1-naphthylpiperazine (1-NP), possesses a high affinity for 5-HT1 (Ki = 5 nM) and 5-HT2 (Ki = 18 nM) sites. 1-NP produces stimulus effects similar to those of TFMPP and is able to antagonize the stimulus effects produced by DOM.The present results suggest that the unsubstituted benzene ring of quipazine, and of its 1-deaza analogue 2-naphthylpiperazine, makes a significant contribution to the binding of these agents to 5-HT2 sites and, more importantly, may account for their 5-HT2 agonist properties.

COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9)

The present disclosure relates to novel compounds, methods, and compositions capable of binding to PCSK9, thereby modulating PCSK9 proprotein convertase enzyme activity. The compounds of the disclosure include compounds Formula (I).

Small Molecule Antagonists of the Nuclear Androgen Receptor for the Treatment of Castration-Resistant Prostate Cancer

After a high-throughput screening campaign identified thioether 1 as an antagonist of the nuclear androgen receptor, a zone model was developed for structure-activity relationship (SAR) purposes and analogues were synthesized and evaluated in a cell-based luciferase assay. A novel thioether isostere, cyclopropane (1S,2R)-27, showed the desired increased potency and structural properties (stereospecific SAR response, absence of a readily oxidized sulfur atom, low molecular weight, reduced number of flexible bonds and polar surface area, and drug-likeness score) in the prostate-specific antigen luciferase assay in C4-2-PSA-rl cells to qualify as a new lead structure for prostate cancer drug development.

Practical method for parallel synthesis of diversely substituted 1-phenylpiperazines

A simple and practical method to prepare 'libraries' of substituted 1-phenylpiperazine building blocks in parallel format has been developed.

Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl) ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: Potent in vivo activity in Parkinson's disease anima

Here we report structure - activity relationship study of a novel hybrid series of compounds where structural alteration of aromatic hydrophobic moieties connected to the piperazine ring and bioisosteric replacement of the aromatic tetralin moieties were

Discovery of imidazole carboxamides as potent and selective CCK1R agonists

High-throughput screening revealed diaryl pyrazole 3 as a selective albeit modest cholecystokinin 1 receptor (CCK1R) agonist. SAR studies led to the discovery and optimization of a novel class of 1,2-diaryl imidazole carboxamides. Compound 44, which was profiled extensively, showed good in vivo mouse gallbladder emptying (mGBE) and lean mouse overnight food intake (ONFI) reduction activities.

Novel N-acylated heterocycles

Described are compositions comprising a muscarinic receptor antagonist and an N-acylated heterocycle derivative having affinity for serotonergic receptors, and enantiomers, diastereoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts thereof. The combination of a muscarinic receptor antagonist and an N-acylated heterocycle, or an enantiomer, diastereoisomer, N-oxide, polymorph, solvate or pharmaceutically acceptable salt thereof, is useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT1A receptors.

Utilization of pyrimidine derivatives for preventing and treating cerebral ischaemia

Use of pyrimidine derivatives of the formula I where the substituents are as defined in the description, and of their physiologically tolerated salts for producing medicaments for the prophylaxis and treatment of cerebral ischemia and strokes.

Synthesis and molecular modeling of new 1-aryl-3-[4-arylpiperazin-1-yl]-1-propane derivatives with high affinity at the serotonin transporter and at 5-HT1A receptors

It has been proposed that 5-HT1A receptor antagonists augment the antidepressant efficacy of selective serotonin (5-HT) reuptake inhibitors. In a search toward new and efficient antidepressants, 1-(aryl)-3-[4-arylpiperazin-1-yl]-1-propane molecular hybrids were designed, synthesized, and evaluated for 5-HT reuptake inhibition and 5-HT1A receptor affinity. The design was based in coupling structural moieties related to inhibition of serotonin reuptake, such as benzo[b]-thiophene derivatives to arylpiperazines, typical 5-HT1A receptor ligands. In binding studies, several compounds showed affinity at the 5-HT transporter and at 5-HT1A receptors. Molecular modeling studies predicted the pharmacophore elements required for high affinity binding and the features that enable to discriminate between agonist, partial agonist, or antagonist action at 5-HT1A receptors and 5-HT transporter inhibition. Solvent interactions in desolvation prior to the binding step along with enthalpy and enthropy compensations might be responsible to explain agonist, partial agonist, and antagonist character. Hydrogen-bonding capability seems to be important to break hydrogen interhelical hydrogen bonds or alternatively to form other bonds upon ligand binding. Partial agonists and antagonists are unable to do this as the full agonist, which interacts closely by long-range forces or directly. The compounds showing the higher affinity at both the 5-HT transporter (Ki 1A receptors (Ki 35S]GTPγS binding or to antagonize 8-hydroxy-2-di-n-propylamino-tetralin (8-OH-DPAT)-stimulated [35]GTPγS binding to rat hippocampal membranes, an index of agonist/antagonist action at 5-HT1A receptors, respectively. Compound 8g exhibited agonist activity (EC50 = 30 nM) in this assay, whereas compounds 7g and 8h,i behaved as weak partial agonists and 7h-j and 8j,1 antagonized the R(+)-8-OH-DPAT-stimulated GTPγS binding. Functional characterization was performed by measuring the antagonism to 8-OH-DPAT-induced hypothermia in mice.

Nickel-catalysed selective N-arylation or N,N′-diarylation of secondary diamines

The selective synthesis of N-aryl or N,N′-diaryl piperazines and trimethylene(bis)piperidines from the corresponding diamines and aryl chlorides using a catalyst combination of Ni(0) associated to 2,2′-bipyridine is described. The Ni/2,2′-bipyridine catalyst is also effective for the sequential arylation of piperazine. The preparation of novel and unsymmetrical 1,4-diaryl piperazines is reported.